Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Nov;69(11):7152–7158. doi: 10.1128/jvi.69.11.7152-7158.1995

Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

S H Pincus 1, R Cole 1, R Ireland 1, F McAtee 1, R Fujisawa 1, J Portis 1
PMCID: PMC189636  PMID: 7474136

Abstract

We have used an experimental retrovirus infection to study the roles played by different antibodies in resistance to both infection and disease. A molecularly cloned chimeric murine leukemia virus was used to induce acute lethal neurological disease in neonatal mice. A panel of monoclonal antibodies directed against the Gag and Env proteins was tested for protective efficacy. In vitro neutralization assays demonstrated that anti-Env antibodies gave different degrees of neutralization, while no anti-Gag neutralized the virus. In vivo experimental endpoints were onset of clinical signs and premoribund condition. As expected, different anti-Env antibodies demonstrated different degrees of protection which correlated with their neutralizing abilities. Surprisingly, anti-Gag antibodies directed against both p15 (MA protein) and p30 (CA protein) were also protective, significantly delaying the onset of disease. No protection was seen with either of two control antibodies. The protection with anti-Gag was dose related and time dependent and was also produced with Fab fragments. Treatment with anti-Gag did not prevent viremia but resulted in a slight slowing in viremia kinetics and decreased levels of virus in the central nervous systems of mice protected from disease. These data indicate that nonneutralizing antiretroviral antibodies can influence the outcome of retroviral disease. The data also suggest a functional role for cell surface expression of Gag proteins on murine leukemia virus-infected cells.

Full Text

The Full Text of this article is available as a PDF (307.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolognesi D. P. AIDS. Do antibodies enhance the infection of cells by HIV? Nature. 1989 Aug 10;340(6233):431–432. doi: 10.1038/340431a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Britt W. J., Chesebro B. Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol. 1983 May;130(5):2363–2367. [PubMed] [Google Scholar]
  3. Chesebro B., Britt W., Evans L., Wehrly K., Nishio J., Cloyd M. Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology. 1983 May;127(1):134–148. doi: 10.1016/0042-6822(83)90378-1. [DOI] [PubMed] [Google Scholar]
  4. Chesebro B., Wehrly K., Cloyd M., Britt W., Portis J., Collins J., Nishio J. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology. 1981 Jul 15;112(1):131–144. doi: 10.1016/0042-6822(81)90619-x. [DOI] [PubMed] [Google Scholar]
  5. Corbin A., Prats A. C., Darlix J. L., Sitbon M. A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol. 1994 Jun;68(6):3857–3867. doi: 10.1128/jvi.68.6.3857-3867.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Czub M., Czub S., McAtee F. J., Portis J. L. Age-dependent resistance to murine retrovirus-induced spongiform neurodegeneration results from central nervous system-specific restriction of virus replication. J Virol. 1991 May;65(5):2539–2544. doi: 10.1128/jvi.65.5.2539-2544.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Czub M., McAtee F. J., Portis J. L. Murine retrovirus-induced spongiform encephalomyelopathy: host and viral factors which determine the length of the incubation period. J Virol. 1992 Jun;66(6):3298–3305. doi: 10.1128/jvi.66.6.3298-3305.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Czub S., Lynch W. P., Czub M., Portis J. L. Kinetic analysis of spongiform neurodegenerative disease induced by a highly virulent murine retrovirus. Lab Invest. 1994 May;70(5):711–723. [PubMed] [Google Scholar]
  9. Edwards S. A., Fan H. Sequence relationship of glycosylated and unglycosylated gag polyproteins of Moloney murine leukemia virus. J Virol. 1980 Jul;35(1):41–51. doi: 10.1128/jvi.35.1.41-51.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  11. Evans L. H., Morrison R. P., Malik F. G., Portis J., Britt W. J. A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol. 1990 Dec;64(12):6176–6183. doi: 10.1128/jvi.64.12.6176-6183.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Golding H., D'Souza M. P., Bradac J., Mathieson B., Fast P. Neutralization of HIV-1. AIDS Res Hum Retroviruses. 1994 Jun;10(6):633–643. doi: 10.1089/aid.1994.10.633. [DOI] [PubMed] [Google Scholar]
  13. Gould E. A., Buckley A., Barrett A. D., Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol. 1986 Mar;67(Pt 3):591–595. doi: 10.1099/0022-1317-67-3-591. [DOI] [PubMed] [Google Scholar]
  14. Laurent A. G., Krust B., Rey M. A., Montagnier L., Hovanessian A. G. Cell surface expression of several species of human immunodeficiency virus type 1 major core protein. J Virol. 1989 Sep;63(9):4074–4078. doi: 10.1128/jvi.63.9.4074-4078.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lefrancois L. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J Virol. 1984 Jul;51(1):208–214. doi: 10.1128/jvi.51.1.208-214.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mathews J. H., Roehrig J. T., Trent D. W. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol. 1985 Sep;55(3):594–600. doi: 10.1128/jvi.55.3.594-600.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McAtee F. J., Portis J. L. Monoclonal antibodies specific for wild mouse neurotropic retrovirus: detection of comparable levels of virus replication in mouse strains susceptible and resistant to paralytic disease. J Virol. 1985 Dec;56(3):1018–1022. doi: 10.1128/jvi.56.3.1018-1022.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nakanaga K., Yamanouchi K., Fujiwara K. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J Virol. 1986 Jul;59(1):168–171. doi: 10.1128/jvi.59.1.168-171.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Naso R. B., Stanker L. H., Kopchick J. J., Ng V. L., Karshin W. L., Arlinghaus R. B. Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: identification of an N-terminal 45,000-dalton cleavage product. J Virol. 1983 Mar;45(3):1200–1206. doi: 10.1128/jvi.45.3.1200-1206.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Old L. J., Stockert E., Boyse E. A., Geering G. A study of passive immunization against a transplanted G+ leukemia with specific antiserum. Proc Soc Exp Biol Med. 1967 Jan;124(1):63–68. doi: 10.3181/00379727-124-31667. [DOI] [PubMed] [Google Scholar]
  21. Papsidero L. D., Sheu M., Ruscetti F. W. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol. 1989 Jan;63(1):267–272. doi: 10.1128/jvi.63.1.267-272.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pincus S. H., Cole R. L., Hersh E. M., Lake D., Masuho Y., Durda P. J., McClure J. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J Immunol. 1991 Jun 15;146(12):4315–4324. [PubMed] [Google Scholar]
  23. Pincus S. H., Cole R. L., Kamanga-Sollo E., Fischer S. H. Interaction of group B streptococcal opacity variants with the host defense system. Infect Immun. 1993 Sep;61(9):3761–3768. doi: 10.1128/iai.61.9.3761-3768.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pincus S. H., Messer K. G., Hu S. L. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. J Clin Invest. 1994 Jan;93(1):140–146. doi: 10.1172/JCI116937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pincus S. H., Messer K. G., Nara P. L., Blattner W. A., Colclough G., Reitz M. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest. 1994 Jun;93(6):2505–2513. doi: 10.1172/JCI117260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pincus S. H., Messer K. G., Schwartz D. H., Lewis G. K., Graham B. S., Blattner W. A., Fisher G. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest. 1993 May;91(5):1987–1996. doi: 10.1172/JCI116420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Portis J. L., Czub S., Garon C. F., McAtee F. J. Neurodegenerative disease induced by the wild mouse ecotropic retrovirus is markedly accelerated by long terminal repeat and gag-pol sequences from nondefective Friend murine leukemia virus. J Virol. 1990 Apr;64(4):1648–1656. doi: 10.1128/jvi.64.4.1648-1656.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Portis J. L., Spangrude G. J., McAtee F. J. Identification of a sequence in the unique 5' open reading frame of the gene encoding glycosylated Gag which influences the incubation period of neurodegenerative disease induced by a murine retrovirus. J Virol. 1994 Jun;68(6):3879–3887. doi: 10.1128/jvi.68.6.3879-3887.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Robinson W. E., Jr, Montefiori D. C., Mitchell W. M., Prince A. M., Alter H. J., Dreesman G. R., Eichberg J. W. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4710–4714. doi: 10.1073/pnas.86.12.4710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schmaljohn A. L., Johnson E. D., Dalrymple J. M., Cole G. A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature. 1982 May 6;297(5861):70–72. doi: 10.1038/297070a0. [DOI] [PubMed] [Google Scholar]
  31. Schultz A. M., Rabin E. H., Oroszlan S. Post-translational modification of Rauscher leukemia virus precursor polyproteins encoded by the gag gene. J Virol. 1979 Apr;30(1):255–266. doi: 10.1128/jvi.30.1.255-266.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schwartz D. H., Gorse G., Clements M. L., Belshe R., Izu A., Duliege A. M., Berman P., Twaddell T., Stablein D., Sposto R. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993 Jul 10;342(8863):69–73. doi: 10.1016/0140-6736(93)91283-r. [DOI] [PubMed] [Google Scholar]
  33. Shang F., Huang H., Revesz K., Chen H. C., Herz R., Pinter A. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells. J Virol. 1991 Sep;65(9):4798–4804. doi: 10.1128/jvi.65.9.4798-4804.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sitbon M., Sola B., Evans L., Nishio J., Hayes S. F., Nathanson K., Garon C. F., Chesebro B. Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell. 1986 Dec 26;47(6):851–859. doi: 10.1016/0092-8674(86)90800-7. [DOI] [PubMed] [Google Scholar]
  35. Tung J. S., Yoshiki T., Fleissner E. A core polyprotein of murine leukemia virus on the surface of mouse leukemia cells. Cell. 1976 Dec;9(4 Pt 1):573–578. doi: 10.1016/0092-8674(76)90039-8. [DOI] [PubMed] [Google Scholar]
  36. Zhang Y. X., Stewart S. J., Caldwell H. D. Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect Immun. 1989 Feb;57(2):636–638. doi: 10.1128/iai.57.2.636-638.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES